Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinoma
Phase 2
- Conditions
- renal cell carcinoma
- Registration Number
- JPRN-UMIN000008769
- Lead Sponsor
- Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with history of hypersensitivity against everolimus or sirolimus derivative 2) Pregnant, pregnancy suspect, nursing women, patients who plan to have a baby 3) Patients judged ineligible to participate in the study by the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does Everolimus target in metastatic renal cell carcinoma (mRCC) progression?
How does Everolimus compare to tyrosine kinase inhibitors like sunitinib in treating mRCC patient outcomes?
Which biomarkers correlate with Everolimus response in phase II observational studies of mRCC?
What adverse events are associated with Everolimus in TACT-R sponsored mRCC trials and management strategies?
Are mTOR inhibitors like Everolimus being combined with immunotherapies for advanced renal cell carcinoma?